Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes

被引：2
|
作者：
Sabouret, Pierre Francois [1 ,2 ]
Dib, Jean-Claude [2 ]
Ecarnot, Fiona [3 ,7 ]
Banach, Maciej [4 ,5 ]
Lellouche, Nicolas [6 ]
机构：
[1] Sorbonne Univ, Pitie Salpetriere Hosp,AP HP, Cardiol Inst, INSERM,UMRS 1166,ACT Study Grp, Paris, France
[2] Coll Natl Cardiol Francais, Paris, France
[3] Univ Hosp Besancon, Dept Cardiol, Besancon, France
[4] Med Univ Lodz, Dept Prevent Cardiol & Lipidol, Lodz, Poland
[5] Univ Zielona Gora, Cardiovasc Res Ctr, Zielona Gora, Poland
[6] Henri Mondor Hosp, APHP, Dept Cardiol, Creteil, France
[7] Univ Hosp Besancon, Dept Cardiol, Besancon, France
来源：
ARCHIVES OF MEDICAL SCIENCE | 2023年 / 19卷 / 06期
关键词：
cardiovascular disease; icosapent ethyl (EPA); medical therapy; triglycerides; diabetes mellitus;
D O I：
10.5114/aoms/173511
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Introduction: We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). Methods: Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020. Results: 574 patients were included; mean age 71 years, 81% males, with a high prevalence of other risk factors (81% hypertension). Mean lipid-density lipoprotein cholesterol was 85 mg/dl, mean glycated hemoglobin HbA1c 7.1%, mean triglycerides 148 mg/dl; 82% received statins. Based on National Lipid Association criteria, 31% would be eligible for EPA. Conclusions: In this contemporary survey in consecutive, unselected CAD patients in daily practice, almost a third would be potentially eligible for EPA.
引用
收藏
页码：1901 / 1903
页数：3
相关论文
共 50 条
  • [1] ELIGIBILITY OF ICOSAPENT ETHYL (EPA) IN A FRENCH POPULATION OF CORONARY OUTPATIENTS WITH TYPE 2 DIABETES
    Sabouret, P.
    Dib, J. C.
    Dievart, F.
    Sharareh, A.
    Gallo, A.
    Guedj-Meynier, D.
    Huberman, J. -P.
    Cohen, S.
    Hoffman, O.
    Ouazana, L.
    Assouline, S.
    Lequeux, B.
    Khanoyan, P.
    Biondi-Zoccai, G.
    Rosencher, J.
    Tokgozoglu, L.
    Banach, M.
    Lellouche, N.
    ATHEROSCLEROSIS, 2023, 379 : S91 - S91
  • [2] ELIGIBILITY OF PATIENTS FOR ICOSAPENT ETHYL ACID (EPA) IN AN ARGENTINE REAL-WORLD POPULATION WITH TYPE 2 DIABETES MELLITUS
    Cobo, Augusto Lavalle
    Destaville, Josefina
    Forte, Ezequiel
    Corral, Pablo
    ATHEROSCLEROSIS, 2024, 395
  • [3] Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV
    Kim, Joseph M.
    Bhatt, Deepak L.
    Dagogo-Jack, Samuel
    Cherney, David
    Cosentino, Francesco
    McGuire, Darren K.
    Pratley, Richard E.
    Liu, Chih-Chin
    Cater, Nilo B.
    Frederich, Robert
    Mancuso, James P.
    Cannon, Christopher P.
    DIABETES, 2022, 71
  • [4] Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease
    Kim, Joseph M.
    Bhatt, Deepak L.
    Dagogo-Jack, Samuel
    Cherney, David Z. I.
    Cosentino, Francesco
    McGuire, Darren K.
    Pratley, Richard E.
    Liu, Chih-Chin
    Cater, Nilo B.
    Frederich, Robert
    Mancuso, James P.
    Cannon, Christopher P.
    DIABETES OBESITY & METABOLISM, 2023, 25 (05): : 1398 - 1402
  • [5] Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it
    Lan, Nick S. R.
    Fegan, P. Gerry
    Yeap, Bu B.
    Rankin, James M.
    Watts, Gerald F.
    DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1734 - 1736
  • [6] Prevalence of Anxiety and Depression among Outpatients With Type 2 Diabetes in the Mexican Population
    Escalante Minaya, Stephany
    Tovilla Zarate, Carlos
    Solis Vidal, Samantha
    Vazquez, Silvia
    Juarez, Isela
    Peralta, Yesenia
    Martinez, Fatima
    Jimenez Santos, Maria
    Bermudez Ocana, Deysi
    Ramon Frias, Teresa
    Baeza, Raymundo
    Reyes Tovilla, Jorge
    Lopez Narvaez, Lilia
    DIABETES, 2012, 61 : A384 - A384
  • [7] Prevalence of Anxiety and Depression among Outpatients with Type 2 Diabetes in the Mexican Population
    Tovilla-Zarate, Carlos
    Juarez-Rojop, Isela
    Peralta Jimenez, Yesenia
    Antonia Jimenez, Maria
    Vazquez, Silvia
    Bermudez-Ocana, Deysi
    Ramon-Frias, Teresa
    Genis Mendoza, Alma D.
    Pool Garcia, Sherezada
    Lopez Narvaez, Lilia
    PLOS ONE, 2012, 7 (05):
  • [8] Risk factors and complications in type 2 diabetes outpatients
    Flavio Silva, Ellen Fernandes
    Mendes Ferreira, Cristiane Maria
    De Pinho, Lucineia
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2017, 63 (07): : 621 - 627
  • [9] The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population
    Erbey, JR
    Kuller, LH
    Becher, DJ
    Orchard, TJ
    DIABETES CARE, 1998, 21 (04) : 610 - 614
  • [10] Pregestational diabetes (type 1 and 2), gestational diabetes: data from the French population in 2011
    Billionnet, C.
    Weill, A.
    Ricordeau, P.
    Alla, F.
    Mitanchez, D.
    Hartemann, A.
    Jacqueminet, S.
    DIABETOLOGIA, 2014, 57 : S71 - S71
12345